[1] 崔富强,庄辉. 中国建国以来防控病毒性肝炎工作进展. 中华肝脏病杂志,2021,29:725-731.
[2] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2019年版). 实用肝脏病杂志,2020,23:33-52.
[3] 王晓忠,魏来. 中国慢性丙型肝炎基因3型患者的现状、治疗和展望. 中华肝脏病杂志,2020,28:824-826.
[4] Welzel TM, Bhardwaj N, Hedskog C, et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol, 2017,67:224-236.
[5] Chen Y, Yu C, Yin X, et al. Hepatitis C virus genotypes and subtypes circulating in mainland China. Emerg Microbes Infect, 2017,6:e95.
[6] 白娜. 血清HCV-RNA载量及抗-HCV浓度检测在丙型肝炎临床诊断中的应用分析. 临床血液学杂志,2018,31:922-924.
[7] 国家卫生和计划生育委员会. WS 213—2018丙型肝炎诊断. 临床肝胆病杂志,2018,34:1619-1621.
[8] 朱海超,甘建和. 南阳地区丙型病毒性肝炎患者病历资料分析. 中国艾滋病性病,2019,25:285-288.
[9] Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am, 2015,44:717-734.
[10] Hissar SS, Goyal A, Kumar M, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol, 2006,78:452-458.
[11] 冯小飞,丁国伟,俞海亮,等. 医疗机构丙型肝炎诊断治疗现况研究. 中国艾滋病性病,2020,26:247-249.
[12] 赵会霞,孙书芳,王同显. 隐匿性丙型肝炎病毒流行病学特点与输血安全. 中国输血杂志,2021,34:793-796.
[13] Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol, 1993,74:2391-2399.
[14] Yang R, Cong X, Du S, et al. Performance comparison of the versant HCV genotype 2.0 assay (LiPA) and the abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6. J Clin Microbiol, 2014,52:3685-3692.
[15] Asselah T, Bièche I, Mansouri A, et al. In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol, 2010,221:264-274.
[16] Baiocchini A, Montaldo C, Conigliaro A, et al. Extracellular matrix molecular remodeling in human liver fibrosis evolution. PLoS One, 2016,11:e0151736.
[17] Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol, 2007,9:1089-1097.
[18] Wei L, Omata M, Lim YS, et al. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in mainland China. Antiviral Res, 2018,158:178-184.
[19] Lu J, Feng Y, Chen L, et al. Subtype-specific prevalence of hepatitis c virus ns5a resistance associated substitutions in mainland China. Front Microbiol, 2019,10:535.
[20] Schvarcz R, Ando Y, Sönnerborg A, et al. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol, 1995,23:17-21.
[21] McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther, 2019,17:775-785.
[22] Wei L, Lim SG, Xie Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol, 2019,4:127-134.
[23] Hu C, Yuan G, Liu J, et al. Sofosbuvir-based therapies for patients with hepatitis c virus infection: real-world experience in China. Can J Gastroenterol Hepatol, 2018,2018:3908767.
[24] Mei YY, Chen YM, Wu YK, et al. Efficacy and safety of sofosbuvir-based direct-acting antiviral agents treatment for patients with genotype 3/6 hepatitis C virus infection. Can J Gastroenterol Hepatol, 2020,2020:8872120.
[25] Mehta V, Mahajan R, Midha V, et al. Impact of direct acting antiviral therapy for treatment of hepatitis C genotypes 1, 3 and 4: a real life experience from India. J Clin Exp Hepatol, 2018,8:7-14.
[26] Ji F, Li J, Liu L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b. J Gastroenterol Hepatol, 2021,36:767-774.
[27] Wei L, Wang G, Alami NN, et al. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol, 2020,5:839-849.
[28] Gao Y, Kong F, Li G, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial. Liver Int, 2020,40:2685-2693.
[29] Wei L, Xie Q, Hou JL, et al. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China. J Gastroenterol Hepatol, 2018,33:1168-1176.
[30] Huang R, Rao H, Xie Q, et al. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol, 2019,91:1313-1318. |
